ShangBay Capital

VC Palo Alto, United States · Founded 2015

ShangBay Capital actively partners with early-stage founders to back disruptive medical devices, biotechnology, and healthcare technology innovations that address high, unmet clinical needs.

About ShangBay Capital

ShangBay Capital is a US-based venture firm with a thesis at the intersection of US healthcare and life sciences and the Chinese strategic capital and commercial ecosystem, investing in biotech, medical devices, diagnostics, and selectively digital health. Stage focus is typically Series A and B, with checks plausibly in the $2M to $8M range and the capacity to participate in larger syndicates. Healthcare exposure is exclusive and runs through therapeutics, novel modalities, devices with clear regulatory paths, and selectively digital health platforms with cross-border opportunities between the US and China. Physician founders building biotech assets, medical devices, or digital health with credible US-China cross-border potential are the right profile. Founders building consumer wellness brands, pure-play SaaS without healthcare anchoring, or US-only commercial models with no China-relevant strategy should pitch elsewhere. Geographic posture is bicoastal US with active China-bridging activity. The realistic entry path is a warm introduction from a co-investing healthcare specialist, a clinician advisor with cross-border expertise, or a Chinese strategic operator in the network. Founders should arrive with KOL scientific support, defended IP, a clear regulatory plan, and a credible cross-border commercial narrative when relevant. Treat ShangBay as a focused US-China bridge investor for healthcare and life-sciences companies, more than a generalist option.

Founder reviews

No founder reviews yet. Raised from this fund? Share your experience with other founders.

Healthcare AI tools backed by ShangBay Capital

Tools made by companies in ShangBay Capital's portfolio that we cover in the directory.

Ceribell Delirium Monitor System
Ceribell
Neurology AI
The Ceribell Delirium Monitor System is an AI-powered, point-of-care EEG platform for rapid diagnosis and continuous monitoring of delirium and seizures in acute care settings.
Ceribell Status Epilepticus Monitor
Ceribell
Neurology AI
Ceribell offers a novel, point-of-care EEG system with AI-powered algorithms for rapid diagnosis and continuous monitoring of serious neurological conditions like status epilepticus, delirium, and suspected LVO stroke in acute care settings.
PeriCALM Patterns
PeriGen
OB/GYN AI
PeriCALM Patterns by PeriGen is an AI-powered software for fetal/maternal monitoring, using advanced algorithms to detect and label fetal heart rate patterns and uterine contractions, providing clinical decision support and integrating with EHR systems to enhance perinatal care.
Human API
Human API
Developer Tools & APIs
Human API is a patient-centric platform that aggregates, normalizes, and provides secure access to health data from diverse sources, empowering consumers to control and share their medical information with trusted applications and organizations.
Arrived
Arrived
Physician Real Estate
Arrived allows physicians to invest in fractional rental property ownership with a low entry cost, providing passive income and appreciation potential without the operational burden of direct ownership.

Portfolio companies in our directory

Other portfolio companies

Companies in ShangBay Capital's portfolio not currently in our directory.

Team

William Dai
Founding Managing Partner
Chaucer Shen
Managing Partner
Erik T. Engelson
Venture Partner
Michael Wallace
Venture Partner
Yajun Xu, Ph.D.
Senior Advisor
Cindy Costello
Director of Finance & Administration

Pitch / review this investor

Have you raised from ShangBay Capital? Founders only — share your honest experience (anonymous OK, moderated before publishing).

Share your experience
Last updated 2026-05-06. Sourced from this fund's published materials.
AI Tool Finder
AI-powered search. Results may not be comprehensive.